The calculation of earnings per share for the three months ended March 31, 2026 and 2025 are as follows:
| Schedule of earnings per share |
|
|
|
|
|
|
|
|
| |
|
2025 |
|
|
2024 |
|
| |
|
$ |
|
|
$ |
|
| Net Income (loss) attributable to shareholders |
|
|
(2,702,217 |
) |
|
|
598,782 |
|
| Weighted average number of SV Shares outstanding |
|
|
249,914,536 |
|
|
|
227,189,980 |
|
| Dilutive effect of stock options outstanding |
|
|
- |
|
|
|
26,407 |
|
| Dilutive effect of RSUs outstanding |
|
|
- |
|
|
|
1,668,375 |
|
| Dilutive effect of warrants outstanding |
|
|
- |
|
|
|
2,911,113 |
|
| Diluted weighted average number of SV Shares outstanding |
|
|
249,914,536 |
|
|
|
231,795,875 |
|
| |
|
|
|
|
|
|
|
|
| Basic net income (loss) per share |
|
|
(0.01 |
) |
|
|
0.00 |
|
| Diluted net income (loss) per share |
|
|
(0.01 |
) |
|
|
0.00 |
|
The following table displays the securities that have been excluded from the computation because their effects would be anti-dilutive:
| Schedule of anti-dilutive |
|
|
|
|
|
|
|
|
| |
|
Three months ended
March 31, |
|
| |
|
2026 |
|
|
2025 |
|
| |
|
# |
|
|
# |
|
| Stock options |
|
|
13,665,000 |
|
|
|
- |
|
| RSUs |
|
|
1,496,500 |
|
|
|
- |
|
| Warrants |
|
|
4,000,000 |
|
|
|
- |
|
| Total |
|
|
19,161,500 |
|
|
|
- |
|